Celiac disease is an immune-mediated enteropathy triggered by gluten in genetically predisposed individuals (HLA-DQ2/DQ8), with a global seroprevalence of approximately 1.4%. However, only one in four ...
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
No signs of graft rejection or de novo donor-specific HLA antibodies - Tegoprubart continues to demonstrate a favorable safety and tolerability profile IRVINE, Calif, March 16, 2026 (GLOBE NEWSWIRE) - ...
When a patient undergoes an organ transplant, failure to match the donor and recipient can lead to the recipient's immune system attacking the new organ, a process triggered by a specific HLA (human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results